Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980460 | 0.90 | KDM4E (0.52) | KDM4EMAOBSIGMAR1MAOAXDH | |
| SCHEMBL4980706 | 0.89 | KDM4E (0.51) | KDM4EMAOBSIGMAR1MAOAXDH | |
| SCHEMBL1283645 | 0.88 | KDM4E (0.50) | KDM4EMAOBSIGMAR1MAOA | |
| SCHEMBL4983140 | 0.82 | KDM4E (0.62) | KDM4EMAOBSIGMAR1MAOAXDH | |
| SCHEMBL16406421 | 0.80 | NR1I2 (0.42) | KDM4EMAOAMAPTKMT2A | |
| SCHEMBL2891337 | 0.80 | KDM4E (0.59) | KDM4EMAOBSIGMAR1MAOAXDH | |
| SCHEMBL4986148 | 0.78 | KDM4E (0.48) | KDM4EMAOBSIGMAR1MAOAMAPT | |
| SCHEMBL4984307 | 0.77 | KDM4E (0.50) | KDM4EMAOBSIGMAR1MAOA | |
| SCHEMBL5240129 | 0.77 | KDM4E (0.56) | KDM4EMAOBSIGMAR1MAOAXDH | |
| SCHEMBL2891507 | 0.77 | CYP1A2 (0.60) | KDM4EMAOBSIGMAR1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | TRANS TECH PHARMA, INC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7329684-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7087632-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2006-02-02 | — | — | US | disclosed |
| EP-1387680-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TransTech Pharma Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2003-02-13 | — | — | US | disclosed |
| WO-2002069965-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAOB 1721/4885SIGMAR1 2694/4885 |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3282/4885MAOB 1747/4885SIGMAR1 2866/4885 |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAOB 1721/4885SIGMAR1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.